TABLE IV.
Baseline patient characteristics
| Characteristic |
Group
|
p Valuea | ||
|---|---|---|---|---|
| Nonsurgical | Surgical | Overall | ||
| Patients (n) | 63 | 48 | 111 | |
| Age at diagnosis (years) | ||||
| Mean | 64 | 61 | 63 | 0.196 |
| Range | 28–89 | 35–88 | 28–89 | |
| Tumour stage [% (n)] | ||||
| T4b | 35 (22) | 23 (11) | 29 (32) | 0.15 |
| T3b | 19 (12) | 29 (14) | 23 (26) | 0.42 |
| TX, 1 and 2b | 44 (28) | 52 (25) | 48 (53) | 0.69 |
| Nodal status [% (n)] | ||||
| N3b | 19 (12) | 8 (4) | 14 (16) | 0.123 |
| N2 | 14 (9) | 21 (10) | 17 (19) | 0.51 |
| N1 | 22 (14) | 29 (14) | 25 (28) | 0.54 |
| N0 | 38 (24) | 40 (19) | 39 (43) | 0.90 |
| hr-positive | 76 (48) | 73 (35) | 75 (83) | 0.26 |
| her2-positive | 13 (8) | 29 (14) | 20 (22) | 0.06 |
| Triple-negative | 9 (6) | 10 (5) | 10 (11) | 0.67 |
| Metastasis [% (n)] | ||||
| Visceral | 73 (46) | 67 (32) | 70 (78) | 0.46 |
| Bone only | 24 (15) | 29 (14) | 26 (29) | 0.52 |
| Brain | 13 (8) | 8 (4) | 11 (12) | 0.46 |
a
Nonsurgical group compared with surgical group.
b
Clinical T or N.
hr = hormone receptor; her2 = human epidermal growth factor receptor 2.